A pooled analysis of the IL-10-1082 A/G polymorphism and the nasopharyngeal carcinoma susceptibility

European Archives of Oto-Rhino-Laryngology

Volumn 273, Issue 4, 2016, Pages 819-825

  Ma, Liping ^a   Li, Shan ^a   Lu, Yu ^a   Zhang, Xiaolian ^a   Zhao, Jiangyang ^a   Qin, Xue ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

IL 10; Meta analysis; NPC; Polymorphism

Indexed keywords

INTERLEUKIN 10; DNA; IL10 PROTEIN, HUMAN;

ALLELE; CANCER RISK; CANCER SUSCEPTIBILITY; DNA POLYMORPHISM; GENETIC RISK; HUMAN; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; GENETIC PREDISPOSITION; GENETICS; HEALTH; METABOLISM; MORBIDITY; NASOPHARYNGEAL NEOPLASMS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TRENDS;

DNA, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GLOBAL HEALTH; HUMANS; INTERLEUKIN-10; MORBIDITY; NASOPHARYNGEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL RATE;

EID: 84960468679     PISSN: 09374477     EISSN: 14344726     Source Type: Journal    
DOI: 10.1007/s00405-014-3465-9     Document Type: Review

References (35)

1. Busson P, Keryer C, Ooka T, Corbex M (2004) EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 12:356–360
2. Yu WM, Hussain SS (2009) Incidence of nasopharyngeal carcinoma in Chinese immigrants, compared with Chinese in China and South East Asia: review. J Laryngol Otol 123:1067–1074
3. Cao SM, Simons MJ, Qian CN (2011) The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 30:114–119
4. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4:757–768
5. McDermott AL, Dutt SN, Watkinson JC (2001) The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 26:82–92
6. Chen DL, Huang TB (1997) A case-control study of risk factors of nasopharyngeal carcinoma. Cancer Lett 117:17–22
7. Chang ET, Adami HO (2006) The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15:1765–1777
8. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209–1220
9. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815–3822
10. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S (1993) Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150:353–360
11. Fiorentino DF, Bond MW, Mosmann TR (1989) Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170:2081–2095
12. Uwatoko N, Tokunaga T, Hatanaka H, Osada H, Kawakami T, Yamazaki H, Abe Y et al (2002) Expression of interleukin-10 is inversely correlated with distant metastasis of renal cell carcinoma. Int J Oncol 20:729–733
13. Neuner A, Schindel M, Wildenberg U, Muley T, Lahm H, Fischer JR (2002) Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer 101:287–292
14. Budiani DR, Hutahaean S, Haryana SM, Soesatyo MH, Sosroseno W (2002) Interleukin-10 levels in Epstein-Barr virus-associated nasopharyngeal carcinoma. J Microbiol Immunol Infect 35:265–268
15. Karcher J, Reisser C, Daniel V, Herold-Mende C (1999) Cytokine expression of transforming growth factor-beta2 and interleukin-10 in squamous cell carcinomas of the head and neck. Comparison of tissue expression and serum levels. HNO 47:879–884
16. Fujieda S, Sunaga H, Tsuzuki H, Fan GK, Saito H (1999) IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett 136:1–9
17. Fujieda S, Lee K, Sunaga H, Tsuzuki H, Ikawa H, Fan GK, Imanaka M et al (1999) Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer 85:1439–1445
18. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8
19. Kong F, Liu J, Liu Y, Song B, Wang H, Liu W (2010) Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population. J Exp Clin Cancer Res 29:72
20. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A et al (2008) The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Anticancer Res 28:309–314
21. Howell WM, Turner SJ, Bateman AC, Theaker JM (2001) IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2:25–31
22. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D (2001) Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20:21–35
23. Thakkinstian A, D’Este C, Eisman J, Nguyen T, Attia J (2004) Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res 19:419–428
24. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
26. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
27. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748
28. Pratesi C, Bortolin MT, Bidoli E, Tedeschi R, Vaccher E, Dolcetti R, Guidoboni M et al (2006) Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55:23–30
29. Wei YS, Kuang XH, Zhu YH, Liang WB, Yang ZH, Tai SH, Zhao Y et al (2007) Interleukin-10 gene promoter polymorphisms and the risk of nasopharyngeal carcinoma. Tissue Antigens 70:12–17
30. Farhat K, Hassen E, Gabbouj S, Bouaouina N, Chouchane L (2008) Interleukin-10 and interferon-gamma gene polymorphisms in patients with nasopharyngeal carcinoma. Int J Immunogenet 35:197–205
31. Tsai CW, Tsai MH, Shih LC, Chang WS, Lin CC, Bau DT (2013) Association of Interleukin-10 (IL10) promoter genotypes with nasopharyngeal carcinoma risk in Taiwan. Anticancer Res 33:3391–3396
32. Beck A, Pazolt D, Grabenbauer GG, Nicholls JM, Herbst H, Young LS, Niedobitek G (2001) Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin’s disease. J Pathol 194:145–151
33. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC et al (1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res 56:5499–5505
34. Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson JL, Axelson H et al (2000) Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 96:2568–2573
35. Yilmaz V, Yentur SP, Saruhan-Direskeneli G (2005) IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine 30:188–194